Neurological Biomarkers Global Market Report 2024

Description

A neurological biomarker is a substance that offers objective and quantifiable information regarding the presence, progression, or characteristics of a neurological disorder or condition. These biomarkers play a crucial role in clinical practice, particularly during drug development.

The main categories of neurological biomarkers include proteomics biomarkers, genomics biomarkers, metabolomics biomarkers, imaging biomarkers, and others. Proteomics biomarkers specifically involve proteins or patterns of proteins that can be identified and monitored by analyzing proteins in bodily fluids. These biomarkers find applications in various neurological conditions such as Alzheimer's disease, Parkinson's disease, Huntington's disease, schizophrenia, depression, multiple sclerosis, and spinal muscular atrophy. They are utilized by hospital laboratories, clinical diagnostic centers, research organizations, and other relevant entities.

The neurological biomarkers research report is one of a series of new reports from The Business Research Company that provides neurological biomarkers market statistics, including the neurological biomarkers industry's global market size, regional shares, competitors with neurological biomarkers market share, detailed neurological biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the neurological biomarkers industry. This neurological biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neurological biomarkers market size has grown rapidly in recent years. It will grow from $9.46 billion in 2023 to $10.63 billion in 2024 at a compound annual growth rate (CAGR) of 12.4%. The expansion observed in the historical period can be attributed to factors such as the increasing prevalence of neurological disorders, the aging population, the demand for drug development, increased funding for neurological research, and the growing focus on personalized medicine.

The neurological biomarkers market size is expected to see rapid growth in the next few years. It will grow to $17.18 billion in 2028 at a compound annual growth rate (CAGR) of 12.7%. The anticipated growth in the forecast period can be attributed to biomarkers for early detection, the development of biosensors, the adoption of wearable devices, global health initiatives, and a patient-centric approach. Major trends in the forecast period include technological innovation in imaging, rapid advances in omics technologies, the integration of artificial intelligence (AI), the use of real-world evidence in biomarker validation, advancements in diagnostic technologies, and collaborative efforts between industry and research institutions.

The anticipated rise in the prevalence of neurological diseases is poised to drive the growth of the neurological biomarker market. Neurological illnesses impact the brain, spinal cord, and the body's nervous system. In the case of neurodegenerative disorders such as Parkinson's disease, neurological biomarkers play a crucial role in providing early diagnoses through pathological, biochemical, and genetic testing. As of December 2022, the Parkinson's Foundation reported an increase in new diagnoses of Parkinson's disease, reaching 90,000 in 2022 compared to 60,000 per year in 2021. This surge underscores the role of neurological biomarkers in addressing the growing prevalence of neurological diseases.

The increasing incidence of schizophrenia is expected to contribute to the growth of the neurological biomarkers market. Schizophrenia, a severe mental health disorder, presents cognitive, emotional, and behavioral symptoms. Neurological biomarkers offer the potential for early detection, objective diagnostic measures, personalized treatment, reduced reliance on subjective assessments, and a deeper understanding of the disorder's neurobiological mechanisms. Globally, approximately 24 million people, or 1 in 300 individuals (0.32%), suffer from schizophrenia, with adults experiencing this at a rate of one in 222 (0.4%), as reported by the World Health Organization in January 2022. This prevalence underscores the significance of neurological biomarkers in addressing conditions such as schizophrenia.

Major companies are forging partnerships to enhance innovation and solidify their market positions. Collaborations, such as the one between NeuroSense Therapeutics Ltd. and NeuraLight, leverage complementary expertise to accelerate the development of biomarkers for neurological disorders. In this case, the partnership aims to identify oculometric indicators for Amyotrophic Lateral Sclerosis (ALS) using Artificial Intelligence (AI) and Machine Learning (ML). Such collaborations facilitate the advancement and commercialization of novel therapies by combining resources and expertise.

Major companies in the neurological biomarkers market are developing innovative products, including advanced biomarker blood tests. Quanterix Corporation, for instance, launched the LucentAD biomarker blood test. This test, analyzing p-Tau 181 levels, aids medical professionals in evaluating patients with cognitive symptoms indicative of Alzheimer's disease. The test is positioned as a diagnostic tool for adults undergoing assessment for Alzheimer's disease but is not intended for standalone screening or diagnosis, emphasizing the need for a comprehensive diagnostic approach.

In May 2021, GE Healthcare acquired Zionexa, a molecular technology company, to expand its portfolio of precision cancer medicines. Zionexa's focus on developing in vivo oncology and neurology biomarkers aligns with GE Healthcare's objectives in advancing medical technology.

Major companies operating in the neurological biomarkers market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Thermos Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories, Boehringer Ingelheim International GmbH, Becton Dickinson and Company, Agilent Technologies Inc., Grifols S.A., Eisai Co. Ltd., PerkinElmer Inc., Illumina Inc., Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Mallinckrodt Plc, Qiagen N.V., Luminex Corporation, Siemens Healthineers, Olink Proteomics, Meso Scale Diagnostics, Quanterix Corp., Fujirebio, Cisbio Bioassays SAS, NeuroVision Imaging, Proteome Sciences Plc, Acumen Pharmaceuticals.

North America was the largest region in the neurological biomarkers market in 2023. The regions covered in the neurological biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the neurological biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The neurological biomarker market consists of sales of genetic testing kits, electroencephalography (EEG) devices, and biomarker assay kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurological Biomarkers Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurological biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurological biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neurological biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Product: Proteomics Biomarker; Genomics Biomarker; Metabolomics Biomarker; Imaging Biomarker; Other Products
2) By Application: Alzheimer's Disease; Parkinson's Disease; Huntington's Disease; Schizophrenia; Depression; Multiple Sclerosis; Spinal Muscular Atrophy
3) By End-User: Hospital Laboratories; Clinical Diagnostic Centers; Research Organizations; Other End-Users
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Novartis AG; Thermos Fisher Scientific Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r14171

1. Executive Summary

2. Neurological Biomarkers Market Characteristics

3. Neurological Biomarkers Market Trends And Strategies

4. Neurological Biomarkers Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Neurological Biomarkers Market Size and Growth

5.1. Global Neurological Biomarkers Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Neurological Biomarkers Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Neurological Biomarkers Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Neurological Biomarkers Market Segmentation

6.1. Global Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Proteomics Biomarker
Genomics Biomarker
Metabolomics Biomarker
Imaging Biomarker
Other Products
6.2. Global Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Alzheimer's Disease
Parkinson's Disease
Huntington's Disease
Schizophrenia
Depression
Multiple Sclerosis
Spinal Muscular Atrophy
6.3. Global Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital Laboratories
Clinical Diagnostic Centers
Research Organizations
Other End-Users

7. Neurological Biomarkers Market Regional And Country Analysis

7.1. Global Neurological Biomarkers Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Neurological Biomarkers Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Neurological Biomarkers Market

8.1. Asia-Pacific Neurological Biomarkers Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Neurological Biomarkers Market

9.1. China Neurological Biomarkers Market Overview
9.2. China Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Neurological Biomarkers Market

10.1. India Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Neurological Biomarkers Market

11.1. Japan Neurological Biomarkers Market Overview
11.2. Japan Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Neurological Biomarkers Market

12.1. Australia Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Neurological Biomarkers Market

13.1. Indonesia Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Neurological Biomarkers Market

14.1. South Korea Neurological Biomarkers Market Overview
14.2. South Korea Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Neurological Biomarkers Market

15.1. Western Europe Neurological Biomarkers Market Overview
15.2. Western Europe Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Neurological Biomarkers Market

16.1. UK Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Neurological Biomarkers Market

17.1. Germany Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Neurological Biomarkers Market

18.1. France Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Neurological Biomarkers Market

19.1. Italy Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Neurological Biomarkers Market

20.1. Spain Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Neurological Biomarkers Market

21.1. Eastern Europe Neurological Biomarkers Market Overview
21.2. Eastern Europe Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Neurological Biomarkers Market

22.1. Russia Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Neurological Biomarkers Market

23.1. North America Neurological Biomarkers Market Overview
23.2. North America Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Neurological Biomarkers Market

24.1. USA Neurological Biomarkers Market Overview
24.2. USA Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Neurological Biomarkers Market

25.1. Canada Neurological Biomarkers Market Overview
25.2. Canada Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Neurological Biomarkers Market

26.1. South America Neurological Biomarkers Market Overview
26.2. South America Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Neurological Biomarkers Market

27.1. Brazil Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Neurological Biomarkers Market

28.1. Middle East Neurological Biomarkers Market Overview
28.2. Middle East Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Neurological Biomarkers Market

29.1. Africa Neurological Biomarkers Market Overview
29.2. Africa Neurological Biomarkers Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Neurological Biomarkers Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Neurological Biomarkers Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Neurological Biomarkers Market Competitive Landscape And Company Profiles

30.1. Neurological Biomarkers Market Competitive Landscape
30.2. Neurological Biomarkers Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. F. Hoffmann-La Roche AG
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Merck & Co. Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Novartis AG
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Thermos Fisher Scientific Inc.
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Neurological Biomarkers Market Other Major And Innovative Companies

31.1. AstraZeneca Plc
31.2. Abbott Laboratories
31.3. Boehringer Ingelheim International GmbH
31.4. Becton Dickinson and Company
31.5. Agilent Technologies Inc.
31.6. Grifols S.A.
31.7. Eisai Co. Ltd.
31.8. PerkinElmer Inc.
31.9. Illumina Inc.
31.10. Shimadzu Corporation
31.11. Waters Corporation
31.12. Bio-Rad Laboratories Inc.
31.13. Mallinckrodt Plc
31.14. Qiagen N.V.
31.15. Luminex Corporation

32. Global Neurological Biomarkers Market Competitive Benchmarking

33. Global Neurological Biomarkers Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Neurological Biomarkers Market

35. Neurological Biomarkers Market Future Outlook and Potential Analysis

35.1 Neurological Biomarkers Market In 2028 - Countries Offering Most New Opportunities
35.2 Neurological Biomarkers Market In 2028 - Segments Offering Most New Opportunities
35.3 Neurological Biomarkers Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer